X‐linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Adrenoleukodystrophy (ALD) is a rare X‐linked disease caused by a mutation of the peroxisomal ABCD1 gene. This review summarizes our current understanding of the pathogenic cell‐ and tissue‐specific roles of lipid species in the context of experimental therapeutic strategies and provides an overview of critical historical developments, therapeutic trials and the advent of newborn screening in the USA. In ALD, very long‐chain fatty acid (VLCFA) chain length‐dependent dysregulation of endoplasmic reticulum stress and mitochondrial radical generating systems inducing cell death pathways has been shown, providing the rationale for therapeutic moiety‐specific VLCFA reduction and antioxidant strategies. The continuing increase in newborn screening programs and promising results from ongoing and recent therapeutic investigations provide hope for ALD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free Radicals in Biology and Medicine
Halliwell, B., & Gutteridge, J. M. C. (2015) · doi:10.1093/acprof:oso/9780198717478.001.0001 · Cited by 8,990
Mitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release
Zorov, D. B., Juhaszova, M., & Sollott, S. J. (2014) · Physiological Reviews · doi:10.1152/physrev.00026.2013 · Cited by 5,383
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 2×
“correction of CD34-positive stem cells is ongoing(Cartier et al., 2009; Eichler et al., 2017).”
BackgroundPutative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
Mosser, J., Douar, A.-M., Sarde, C.-O., Kioschis, P., Feil, R., Moser, H., Poustka, A.-M., Mandel, J.-L., & Aubourg, P. (1993) · Nature · doi:10.1038/361726a0 · Cited by 1,202
Dietschy, J. M., & Turley, S. D. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400004-jlr200 · Cited by 1,095 · cited 2×
“…understanding of the ages when there is greatest risk of development of childhood cerebral ALD is the fact that in human plasma the ratio of 24-HC to cholesterol is 5 times higher in the first decade of life than the sixth (Lütjohann et al., 1996; Dietschy and Turley, 2004; Saeed et al., 2014).”
BackgroundLütjohann, D., Breuer, O., Ahlborg, G., Nennesmo, I., Sidén, A., Diczfalusy, U., & Björkhem, I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9799 · Cited by 682
Moser, H. W., Mahmood, A., & Raymond, G. V. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0421 · Cited by 663
Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy
Eichler, F., Duncan, C., Musolino, P. L., Orchard, P. J., De Oliveira, S., Thrasher, A. J., Armant, M., Dansereau, C., Lund, T. C., Miller, W. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700554 · Cited by 604 · cited 1×
“correction of CD34-positive stem cells is ongoing(Cartier et al., 2009; Eichler et al., 2017).”
Cholesterol metabolism in neurons and astrocytes
Pfrieger, F. W., & Ungerer, N. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.06.002 · Cited by 500
Qualitative alteration in substrate specificity of mitochondrial monoamine oxidase in brain
Moskvitina, T. A., Kamyshanskaya, N. S., Kaverina, L. P., & Gorkin, V. Z. (1976) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1976.tb04462.x · Cited by 440
Moser, H. (1981) · doi:10.1212/wnl.31.10.1241 · Cited by 396
Central nervous system: cholesterol turnover, brain development and neurodegeneration
Dietschy, J. M. (2009) · bchm · doi:10.1515/bc.2009.035 · Cited by 394
ELOVL1 production of C24 acyl-CoAs is linked to C24 sphingolipid synthesis
Ohno, Y., Suto, S., Yamanaka, M., Mizutani, Y., Mitsutake, S., Igarashi, Y., Sassa, T., & Kihara, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005572107 · Cited by 382 · cited 1×
“There are 7 ELOVL enzymes; however, ELOVL1, is the one responsible for the chain elongation of VLCFA (Ofman et al., 2010; Ohno et al., 2010).”
BackgroundCholesterol transport through lysosome-peroxisome membrane contacts.
Chu, B.-B., Liao, Y.-C., Qi, W., Xie, C., Du, X., Wang, J., Yang, H., Miao, H.-H., Li, B.-L., & Song, B.-L. (2015) · Cell · doi:10.1016/j.cell.2015.02.019 · Cited by 377
Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes
Kassmann, C. M., Lappe-Siefke, C., Baes, M., Brügger, B., Mildner, A., Werner, H. B., Natt, O., Michaelis, T., Prinz, M., Frahm, J., et al. (2007) · Nature Genetics · doi:10.1038/ng2070 · Cited by 357
Adrenoleukodystrophy: Incidence, new mutation rate, and results of extended family screening
Bezman, L., Moser, A. B., Raymond, G. V., Rinaldo, P., Watkins, P. A., Smith, K. D., Kass, N. E., & Moser, H. W. (2001) · Annals of Neurology · doi:10.1002/ana.101 · Cited by 324
Self-citationKemp, S., Pujol, A., Waterham, H. R., van Geel, B. M., Boehm, C. D., Raymond, G. V., Cutting, G. R., Wanders, R. J. A., & Moser, H. W. (2001) · Human Mutation · doi:10.1002/humu.1227 · Cited by 321 · cited 3×
“In ALD, the VLCFA accumulate in plasma and the cells of all tissues (Kemp et al., 2001).”
BackgroundInfluentialNPTX2 and cognitive dysfunction in Alzheimer’s Disease
Xiao, M.-F., Xu, D., Craig, M. T., Pelkey, K. A., Chien, C.-C., Shi, Y., Zhang, J., Resnick, S., Pletnikova, O., Salmon, D., et al. (2017) · eLife · doi:10.7554/elife.23798 · Cited by 316
A mouse model for X-linked adrenoleukodystrophy
Lu, J.-F., Lawler, A. M., Watkins, P. A., Powers, J. M., Moser, A. B., Moser, H. W., & Smith, K. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9366 · Cited by 293 · cited 7×
“…and zebra fish, the equivalent ABCD1 gene has been successfully targeted to generate knock-out models, each providing a unique strength and limitation (Forss-Petter et al., 1997; Gordon, Valdez, & Letsou, 2018; Kobayashi, Shinnoh, Kondo, & Yamada, 1997; Lu et al., 1997; Strachan et al., 2017).”
BackgroundMethodInfluentialSelf-citationMiller, W. P., Rothman, S. M., Nascene, D., Kivisto, T., DeFor, T. E., Ziegler, R. S., Eisengart, J., Leiser, K., Raymond, G., Lund, T. C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329235 · Cited by 290
X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects
Kemp, S., Berger, J., & Aubourg, P. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.03.012 · Cited by 283 · cited 2×
“However, plasma and cellular antioxidant capacity and ROS generation have been retrospectively associated to disease phenotype (Kemp et al., 2012).”
BackgroundAdrenal insufficiency: still a cause of morbidity and death in childhood
Shulman, D. I., Palmert, M. R., Kemp, S. F., & for the Lawson Wilkins Drug and Therapeutics Committee (2007) · PEDIATRICS · doi:10.1542/peds.2006-1612 · Cited by 282
Adrenoleukodystrophy—Neuroendocrine pathogenesis and redefinition of natural history
Kemp, S., Huffnagel, I. C., Linthorst, G. E., Wanders, R. J., & Engelen, M. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.90 · Cited by 275
Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy
Loes, D. J., Fatemi, A., Melhem, E. R., Gupte, N., Bezman, L., Moser, H. W., & Raymond, G. V. (2003) · Neurology · doi:10.1212/01.wnl.0000079050.91337.83 · Cited by 268 · cited 2×
“MRI with or without contrast enhancement is used to monitor presymptomatic males with ALD for early and progressive white matter changes (Liberato et al., 2019; Eichler et al., 2007; Loes et al., 2003).”
MethodSelf-citationPOWERS, J. M., LIU, Y., MOSER, A. B., & MOSER, H. W. (1992) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199211000-00007 · Cited by 265
Self-citationGene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy
Kemp, S., Wei, H.-M., Lu, J.-F., Braiterman, L. T., McGuinness, M. C., Moser, A. B., Watkins, P. A., & Smith, K. D. (1998) · Nature Medicine · doi:10.1038/3242 · Cited by 249
Self-citationA Two-Year Trial of Oleic and Erucic Acids (“Lorenzo's Oil”) as Treatment for Adrenomyeloneuropathy
Aubourg, P., Adamsbaum, C., Lavallard-Rousseau, M.-C., Rocchiccioli, F., Cartier, N., Jambaque, I., Jakobezak, C., Lemaitre, A., Boureau, F., Wolf, C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309093291101 · Cited by 242
Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil
Moser, H. W., Raymond, G. V., Lu, S.-E., Muenz, L. R., Moser, A. B., Xu, J., Jones, R. O., Loes, D. J., Melhem, E. R., Dubey, P., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1073 · Cited by 239 · cited 2×
“9 years, 24% developed CALD; however, compared to historical data, the percentage of boys that would develop CALD was 37% suggesting a protective effect (Moser et al., 2005).”
BackgroundInfluentialSelf-citationPathophysiology of X-linked adrenoleukodystrophy
Berger, J., Forss-Petter, S., & Eichler, F. S. (2014) · Biochimie · doi:10.1016/j.biochi.2013.11.023 · Cited by 238
X-linked adrenoleukodystrophy in women: A cross-sectional cohort study
Engelen, M., Barbier, M., Dijkstra, I. M. E., Schür, R., de Bie, R. M. A., Verhamme, C., Dijkgraaf, M. G. W., Aubourg, P. A., Wanders, R. J. A., van Geel, B. M., et al. (2014) · Brain · doi:10.1093/brain/awt361 · Cited by 234
Pujol, A. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.499 · Cited by 214 · cited 1×
“As the Abcd1-deficient mouse most resembles the AMN phenotype, developing axonopathy and locomotor impairment at a very late 22 months of age (Pujol et al., 2002); it has been the model of choice for novel therapeutics targeting the spinal cord.”
BackgroundEarly oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy
Fourcade, S., Lopez-Erauskin, J., Galino, J., Duval, C., Naudi, A., Jove, M., Kemp, S., Villarroya, F., Ferrer, I., Pamplona, R., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn085 · Cited by 214
Moser, H. W., Loes, D. J., Melhem, E. R., Raymond, G. V., Bezman, L., Cox, C. S., & Lu, S.-E. (2000) · Neuropediatrics · doi:10.1055/s-2000-9236 · Cited by 210
Bryleva, E. Y., Rogers, M. A., Chang, C. C. Y., Buen, F., Harris, B. T., Rousselet, E., Seidah, N. G., Oddo, S., LaFerla, F. M., Spencer, T. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913828107 · Cited by 209
Pujol, A., Ferrer, I., Camps, C., Metzger, E., Hindelang, C., Callizot, N., Ruiz, M., Pàmpols, T., Giròs, M., & Mandel, J. L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh323 · Cited by 201 · cited 3×
“A double-mutant Abcd1/Abcd2 mouse exhibits higher VLCFA accumulation in the spinal cord (Pujol et al., 2004), higher levels of oxidative damage (Fourcade et al.”
BackgroundHo, J. K., Moser, H., Kishimoto, Y., & Hamilton, J. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118182 · Cited by 199 · cited 1×
“As VLCFA accumulate due to impaired peroxisomal β-oxidation and enhanced FA elongation, elevated levels of VLCFA in membranes could alter structure and function in myelin (Ho et al., 1995).”
BackgroundKobayashi, T., Shinnoh, N., Kondo, A., & Yamada, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6340 · Cited by 197
Mahmood, A., Raymond, G. V., Dubey, P., Peters, C., & Moser, H. W. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70177-1 · Cited by 193
Effects of bile acids on neurological function and disease
McMillin, M., & DeMorrow, S. (2016) · The FASEB Journal · doi:10.1096/fj.201600275r · Cited by 192
Hein, S., Schonfeld, P., Kahlert, S., & Reiser, G. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn066 · Cited by 180 · cited 2×
“, 2003) by keeping some excess saturated or monounsaturated fatty acids in lipid droplets and preventing the induction of necroptosis in oligodendrocytes and astrocytes (Hein et al., 2008; Parisi, Li, & Atilla-Gokcumen, 2017).”
BackgroundHubbard, W. C., Moser, A. B., Liu, A. C., Jones, R. O., Steinberg, S. J., Lorey, F., Panny, S. R., Vogt Jr., R. F., Macaya, D., & Turgeon, C. T. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.03.010 · Cited by 177 · cited 1×
“In 2006 a first newborn screening test for ALD by measurement of C26:0lysophosphatidylcholine, C26:0-LPC in newborn dried blood spot was established (Haynes & De Jesus, 2012; Hubbard et al., 2009, 2006; Raymond, Jones, & Moser, 2007; Theda et al., 2014; Turgeon et al., 2015).”
BackgroundSelf-citationThe role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy
Ofman, R., Dijkstra, I. M. E., van Roermund, C. W. T., Burger, N., Turkenburg, M., van Cruchten, A., van Engen, C. E., Wanders, R. J. A., & Kemp, S. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000061 · Cited by 170
Whitcomb, R. W., Linehan, W. M., & Knazek, R. A. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113292 · Cited by 168
A review of neuroimaging findings in repetitive brain trauma
Koerte, I. K., Lin, A. P., Willems, A., Muehlmann, M., Hufschmidt, J., Coleman, M. J., Green, I., Liao, H., Tate, D. F., Wilde, E. A., et al. (2015) · Brain Pathology · doi:10.1111/bpa.12249 · Cited by 160
Huffnagel, I. C., Laheji, F. K., Aziz-Bose, R., Tritos, N. A., Marino, R., Linthorst, G. E., Kemp, S., Engelen, M., & Eichler, F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01307 · Cited by 147
Dubey, P., Raymond, G. V., Moser, A. B., Kharkar, S., Bezman, L., & Moser, H. W. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.10.067 · Cited by 145 · cited 4×
“Further details regarding clinical have been comprehensively published in multiple reviews (Dubey et al., 2005; Engelen et al., 2014; Huffnagel, Ballegoij, et al., 2019c; Huffnagel, Dijkgraaf, et al., 2019a; Huffnagel, Laheji, et al., 2019b; Moser et al., 2000; Raymond et al., 2018).”
BackgroundInfluentialSelf-citationWiesinger, C., Kunze, M., Regelsberger, G., Forss-Petter, S., & Berger, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.445445 · Cited by 145
Raymond, G. V., Aubourg, P., Paker, A., Escolar, M., Fischer, A., Blanche, S., Baruchel, A., Dalle, J.-H., Michel, G., Prasad, V., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.09.036 · Cited by 142
Berger, J., Wiesinger, C., & Eichler, F. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s49590 · Cited by 140
Fatty acid abnormality in adrenoleukodystrophy
Igarashi, M., Schaumburg, H. H., Powers, J., Kishimoto, Y., Koilodny, E., & Suzuki, K. (1976) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1976.tb04461.x-i1 · Cited by 134
Biochemical aspects of X-linked adrenoleukodystrophy
Kemp, S., & Wanders, R. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00391.x · Cited by 116 · cited 2×
“The saturated straight-chain VLCFA are found in excess in ALD blood and most tissues esterified to glycerophospholipids, lysophospholipids, sphingolipids, acyl-CoAs and acyl-carnitines (Kemp & Wanders, 2010; Moser et al., 2001; van de Beek et al., 2016).”
BackgroundSpastic paraplegia associated with Addison’s disease: Adult variant of adreno-leukodystrophy
Budka, H., Sluga, E., & Heiss, W.-D. (1976) · Journal of Neurology · doi:10.1007/bf00312873 · Cited by 115
Plasmalogens participate in very-long-chain fatty acid-induced pathology
Brites, P., Mooyer, P. A. W., el Mrabet, L., Waterham, H. R., & Wanders, R. J. A. (2008) · Brain · doi:10.1093/brain/awn295 · Cited by 112
Kemper, A. R., Brosco, J., Comeau, A. M., Green, N. S., Grosse, S. D., Jones, E., Kwon, J. M., Lam, W. K. K., Ojodu, J., Prosser, L. A., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.68 · Cited by 109 · cited 6×
“Early diagnosis through family screening of at-risk males, and as of December 2013 in the USA, newborn screening has provided hope for successful treatment for ALD (Raymond, Moser, & Fatemi, 2018).”
BackgroundInfluentialHUBBARD, W., MOSER, A., TORTORELLI, S., LIU, A., JONES, D., & MOSER, H. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.05.001 · Cited by 108 · cited 1×
“In 2006 a first newborn screening test for ALD by measurement of C26:0lysophosphatidylcholine, C26:0-LPC in newborn dried blood spot was established (Haynes & De Jesus, 2012; Hubbard et al., 2009, 2006; Raymond, Jones, & Moser, 2007; Theda et al., 2014; Turgeon et al., 2015).”
BackgroundSelf-citationNewborn Screening for X-Linked Adrenoleukodystrophy
Moser, A., Jones, R., Hubbard, W., Tortorelli, S., Orsini, J., Caggana, M., Vogel, B., & Raymond, G. (2016) · International Journal of Neonatal Screening · doi:10.3390/ijns2040015 · Cited by 106
Self-citationDisease progression in women with X-linked adrenoleukodystrophy is slow
Huffnagel, I. C., Dijkgraaf, M. G. W., Janssens, G. E., van Weeghel, M., van Geel, B. M., Poll-The, B. T., Kemp, S., & Engelen, M. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1008-6 · Cited by 100
The Dorsal Root Ganglia in Adrenomyeloneuropathy: Neuronal Atrophy and Abnormal Mitochondria
Powers, J. M., Deciero, D. P., Cox, C., Richfield, E. K., Ito, M., Moser, A. B., & Moser, H. W. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.5.493 · Cited by 96
Self-citationBrain endothelial dysfunction in cerebral adrenoleukodystrophy
Musolino, P. L., Gong, Y., Snyder, J. M. T., Jimenez, S., Lok, J., Lo, E. H., Moser, A. B., Grabowski, E. F., Frosch, M. P., & Eichler, F. S. (2015) · Brain · doi:10.1093/brain/awv250 · Cited by 92
Self-citationHead trauma can initiate the onset of adreno-leukodystrophy
Raymond, G. V., Seidman, R., Monteith, T. S., Kolodny, E., Sathe, S., Mahmood, A., & Powers, J. M. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.11.005 · Cited by 90 · cited 1×
“Early presence of contrast enhancement on magnetic resonance imaging, MRI, after brain contusion suggest that the disruption of the blood–brain barrier maybe the trigger for inflammatory demyelination (Aubourg, 2015; Raymond et al., 2010).”
BackgroundSchaumburg, H. H. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490390092013 · Cited by 89
Asheuer, M., Bieche, I., Laurendeau, I., Moser, A., Hainque, B., Vidaud, M., & Aubourg, P. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi140 · Cited by 86 · cited 1×
“However, the amounts of VLCFA levels in normal appearing white matter were found to be higher in CALD compared with the levels in pure AMN (Asheuer et al., 2005).”
ResultSelf-citationKoelman (1996) · doi:10.1212/wnl.46.1.112 · Cited by 78 · cited 1×
“The peripheral nerves are also involved, and in ALD women there is often dysesthesia (van Geel et al., 1996).”
BackgroundAdenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy
Gong, Y., Mu, D., Prabhakar, S., Moser, A., Musolino, P., Ren, J., Breakefield, X. O., Maguire, C. A., & Eichler, F. S. (2015) · Molecular Therapy · doi:10.1038/mt.2015.6 · Cited by 74 · cited 2×
“Gong et al. have showed intrathecal delivery of an AAV9 carrying ABCD1 in mice corrected VLCFA metabolism and behavioral outcomes (Gong et al., 2015).”
BackgroundSelf-citationTSUJI, S., SANO, T., ARIGA, T., & MIYATAKE, T. (1981) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a133578 · Cited by 73
Huffnagel, I. C., van de Beek, M.-C., Showers, A. L., Orsini, J. J., Klouwer, F. C. C., Dijkstra, I. M. E., Schielen, P. C., van Lenthe, H., Wanders, R. J. A., Vaz, F. M., et al. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.10.012 · Cited by 73 · cited 1×
“Following the development of the whole blood spot liquid chromatography tandem mass spectroscopy (LC-MS/MS) measurement of C26:0-lysophosphatidyl choline, C26:0LPC, for the diagnosis of newborns with ALD, the Academic Medical Center in Amsterdam has shown that the C26:0-LPC assay accurately diagnoses males with ALD, a…”
MethodSymptoms in carriers of adrenoleukodystrophy relate to skewed X inactivation
Maier, E. M., Kammerer, S., Muntau, A. C., Wichers, M., Braun, A., & Roscher, A. A. (2002) · Annals of Neurology · doi:10.1002/ana.10376 · Cited by 72 · cited 1×
“CALD is rare in ALD females and the few reported cases are due to a Xq27-ter deletion of the non-mutated X, or skewed X-inactivation favoring the mutated X (Hershkovitz et al., 2002; Maier et al., 2002; Migeon et al., 1981).”
BackgroundImpaired plasticity of macrophages in X-linked adrenoleukodystrophy
Weinhofer, I., Zierfuss, B., Hametner, S., Wagner, M., Popitsch, N., Machacek, C., Bartolini, B., Zlabinger, G., Ohradanova-Repic, A., Stockinger, H., et al. (2018) · Brain · doi:10.1093/brain/awy127 · Cited by 72 · cited 1×
“ABCD1 deficiency leads to incomplete establishment of anti-inflammatory responses of macrophages possibly contributing to the rapidly progressive demyelination in CALD (Weinhofer et al., 2018).”
BackgroundMRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy
Liberato, A. P., Mallack, E. J., Aziz-Bose, R., Hayden, D., Lauer, A., Caruso, P. A., Musolino, P. L., & Eichler, F. S. (2019) · Neurology · doi:10.1212/wnl.0000000000007294 · Cited by 69
Histochemical characteristics of the striated inclusions of adrenoleukodystrophy
Johnson, A. B., Schaumburg, H. H., & Powers, J. M. (1976) · Journal of Histochemistry & Cytochemistry · doi:10.1177/24.6.59773 · Cited by 66
Adrenoleukodystrophy: Guidance for adrenal surveillance in males identified by newborn screen
Regelmann, M. O., Kamboj, M. K., Miller, B. S., Nakamoto, J. M., Sarafoglou, K., Shah, S., Stanley, T. L., Marino, R., & Pediatric Endocrine Society Drug and Therapeutics/Rare Diseases Committee (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00920 · Cited by 61 · cited 1×
“Adrenal dysfunction should be closely monitored in all males (Regelmann et al., 2018).”
BackgroundFatty Acid Composition of Human Myelin Proteolipid Protein in Peroxisomal Disorders
Bizzozero, O. A., Zuñiga, G., & Lees, M. B. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb02003.x · Cited by 61
Turgeon, C. T., Moser, A. B., Mørkrid, L., Magera, M. J., Gavrilov, D. K., Oglesbee, D., Raymond, K., Rinaldo, P., Matern, D., & Tortorelli, S. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.11.013 · Cited by 60 · cited 2×
“In 2006 a first newborn screening test for ALD by measurement of C26:0lysophosphatidylcholine, C26:0-LPC in newborn dried blood spot was established (Haynes & De Jesus, 2012; Hubbard et al., 2009, 2006; Raymond, Jones, & Moser, 2007; Theda et al., 2014; Turgeon et al., 2015).”
BackgroundSelf-citationTheda, C., Gibbons, K., DeFor, T. E., Donohue, P. K., Golden, W. C., Kline, A. D., Gulamali-Majid, F., Panny, S. R., Hubbard, W. C., Jones, R. O., et al. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.10.019 · Cited by 56 · cited 2×
“In 2006 a first newborn screening test for ALD by measurement of C26:0lysophosphatidylcholine, C26:0-LPC in newborn dried blood spot was established (Haynes & De Jesus, 2012; Hubbard et al., 2009, 2006; Raymond, Jones, & Moser, 2007; Theda et al., 2014; Turgeon et al., 2015).”
BackgroundSelf-citationKruska, N., Schönfeld, P., Pujol, A., & Reiser, G. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.01.005 · Cited by 56 · cited 2×
“Exposure to VLCFAs C22:0, C24:0 and C26:0 increases ROS generation in both control and ABCD1 knock out astrocytes (Kruska et al., 2015).”
BackgroundFourcade, S., López-Erauskin, J., Ruiz, M., Ferrer, I., & Pujol, A. (2014) · Biochimie · doi:10.1016/j.biochi.2013.09.012 · Cited by 55
Microglial dysfunction as a key pathological change in adrenomyeloneuropathy
Gong, Y., Sasidharan, N., Laheji, F., Frosch, M., Musolino, P., Tanzi, R., Kim, D. Y., Biffi, A., El Khoury, J., & Eichler, F. (2017) · Annals of Neurology · doi:10.1002/ana.25085 · Cited by 54
Raas, Q., Gondcaille, C., Hamon, Y., Leoni, V., Caccia, C., Ménétrier, F., Lizard, G., Trompier, D., & Savary, S. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.02.006 · Cited by 53 · cited 1×
“These cells accumulate VLCFA and have lipid droplets and striated and whorled lipid inclusions (Raas et al., 2019).”
BackgroundABCD1 dysfunction alters white matter microvascular perfusion
Lauer, A., Da, X., Hansen, M. B., Boulouis, G., Ou, Y., Cai, X., Liberato Celso Pedrotti, A., Kalpathy-Cramer, J., Caruso, P., Hayden, D. L., et al. (2017) · Brain · doi:10.1093/brain/awx262 · Cited by 48
C26:0-Carnitine Is a New Biomarker for X-Linked Adrenoleukodystrophy in Mice and Man
van de Beek, M.-C., Dijkstra, I. M. E., van Lenthe, H., Ofman, R., Goldhaber-Pasillas, D., Schauer, N., Schackmann, M., Engelen-Lee, J.-Y., Vaz, F. M., Kulik, W., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154597 · Cited by 48
Strachan, L. R., Stevenson, T. J., Freshner, B., Keefe, M. D., Miranda Bowles, D., & Bonkowsky, J. L. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx249 · Cited by 46 · cited 3×
“species such as the drosophilae, mouse and zebra fish, the equivalent ABCD1 gene has been successfully targeted to generate knock-out models, each providing a unique strength and limitation (Forss-Petter et al., 1997; Gordon, Valdez, & Letsou, 2018; Kobayashi, Shinnoh, Kondo, & Yamada, 1997; Lu et al., 1997; Strachan…”
BackgroundHaynes, C. A., & De Jesús, V. R. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.03.026 · Cited by 46
Hypoperfusion predicts lesion progression in cerebral X-linked adrenoleukodystrophy
Musolino, P. L., Rapalino, O., Caruso, P., Caviness, V. S., & Eichler, F. S. (2012) · Brain · doi:10.1093/brain/aws206 · Cited by 37
Cerebral X‐linked adrenoleukodystrophy in a girl with Xq27‐Ter deletion
Hershkovitz, E., Narkis, G., Shorer, Z., Moser, A. B., Watkins, P. A., Moser, H. W., & Manor, E. (2002) · Annals of Neurology · doi:10.1002/ana.10248 · Cited by 30
Self-citationThe correlation between biochemical and histopathological findings in adrenoleukodystrophy
Reinecke, C. J., Knoll, D. P., Pretorius, P. J., Steyn, H. S., & Simpson, R. H. W. (1985) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(85)90184-4 · Cited by 29
van Engen, C. E., Ofman, R., Dijkstra, I. M. E., van Goethem, T. J., Verheij, E., Varin, J., Vidaud, M., Wanders, R. J. A., Aubourg, P., Kemp, S., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.07.006 · Cited by 26 · cited 1×
“A polymorphism in CYP4F2, the gene that is responsible for peroxisomal ω-oxidation of VLCFA to very long-chain dicarboxylic acids was found to increase the risk of development of childhood onset CALD by decreasing the clearance of VLCFA through ω-oxidation (van Engen et al., 2016).”
BackgroundCerebral adrenoleukodystrophy: a demyelinating disease that leaves the door wide open: Figure 1
Aubourg, P. (2015) · Brain · doi:10.1093/brain/awv271 · Cited by 15 · cited 3×
“Eleven microRNAs were identified that had different expression for CALD and AMN and one of them, MiR196a, was found to inhibit the expression of two inflammatory signaling factors as well as ELOVL1 (Shah & Singh, 2017).”
BackgroundAdreno-leukodystrophy: A personal historical note
Powers, J. M. (2005) · Acta Neuropathologica · doi:10.1007/s00401-004-0961-9 · Cited by 15 · cited 1×
“(Igarashi, Belchis, & Suzuki, 1976b; Khan, Singh, & Singh, 2008; Nury et al., 2017; Powers, 2005).”
Jang, J., Lee, J. W., Song, J., Kim, D., & Min, K. H. (2019) · ChemistryOpen · doi:10.1002/open.201800281 · Cited by 6 · cited 1×
“The study of oligodendrocytes derived from pluripotent stem cells from CALD accumulated more VLCFA than those derived from AMN patients (Jang et al., 2019).”
Background
Cited by
Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy
Gupta, A. O., Raymond, G., Pierpont, E. I., Kemp, S., McIvor, R. S., Rayannavar, A., Miller, B., Lund, T. C., & Orchard, P. J. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2124857 · Cited by 67
Adrenoleukodystrophy Newborn Screening in California Since 2016: Programmatic Outcomes and Follow-Up
Matteson, J., Sciortino, S., Feuchtbaum, L., Bishop, T., Olney, R. S., & Tang, H. (2021) · International Journal of Neonatal Screening · doi:10.3390/ijns7020022 · Cited by 50
Marian, O. C., Teo, J. D., Lee, J. Y., Song, H., Kwok, J. B., Landin-Romero, R., Halliday, G., & Don, A. S. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01544-7 · Cited by 50
Rodríguez-Pascau, L., Vilalta, A., Cerrada, M., Traver, E., Forss-Petter, S., Weinhofer, I., Bauer, J., Kemp, S., Pina, G., Pascual, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc0555 · Cited by 40
Newborn Screening for X-Linked Adrenoleukodystrophy: Review of Data and Outcomes in Pennsylvania
Priestley, J. R. C., Adang, L. A., Drewes Williams, S., Lichter-Konecki, U., Menello, C., Engelhardt, N. M., DiPerna, J. C., DiBoscio, B., Ahrens-Nicklas, R. C., Edmondson, A. C., et al. (2022) · International Journal of Neonatal Screening · doi:10.3390/ijns8020024 · Cited by 35
Metadata
- Authors
- Turk, B. R., Theda, C., Fatemi, A., & Moser, A. B.
- Venue
- International Journal of Developmental Neuroscience
- Publisher
- Wiley
- Published
- 2020-01-26
- Volume
- 80
- Issue
- 1
- Pages
- 52-72
- ISSN
- 0736-5748 (ISSN-L)
- 1873-474X
- OpenAlex
- W2990999800
- Cited by
- 210
- References
- 90
- FWCI
- 16.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.